Elapsed treatment days--a critical item for radiotherapy quality control review in head and neck trials: RTOG report.
For all randomized trials since 1978, the Radiation Therapy Oncology Group has required the study chairman for radiation therapy to review the treatment given to each patient. The chairman scores the compliance of the treatment borders, total dose, fraction, and total elapsed time relative to the protocol prescription at the primary site, regional nodes, and any critical structure. The individual parameters are then considered together to derive an "overall" treatment score. For two RTOG head and neck studies in patients with moderately and very advanced carcinomas, the "overall" treatment was classified as unacceptable if the treatment at primary was scored unacceptable with respect to dose, fractionation, and field borders. However, prolonged elapsed treatment was not included. Analysis of these studies with 426 evaluable patients was performed to assess the relationship of unacceptable "overall" treatment compliance with outcome. Patients with prolonged treatment elapsed days (14 days beyond the protocol prescription) exhibited significantly poorer loco-regional control (13% vs. 27% at 3 years with p = .007) and absolute survival (13% vs. 26% at 3 years with p = .01). As a result, the criteria for unacceptable "overall" treatment were revised to include prolonged elapsed treatment days. Further multivariate analyses showed the revised criteria identified patients with significantly poorer loco-regional control and absolute survival even after adjusting for other prognostic factors.
Pajak
T F
TF
Radiation Therapy Oncology Group Statistical Unit, Philadelphia, PA.
Laramore
G E
GE
Marcial
V A
VA
Fazekas
J T
JT
Cooper
J
J
Rubin
P
P
Curran
W J
WJ
Davis
L W
LW
D002294:Carcinoma, Squamous Cell / Q000188:drug therapy / Q000532:radiotherapy*; D002985:Clinical Protocols; D002986:Clinical Trials as Topic / Q000592:standards*; D003131:Combined Modality Therapy; D006258:Head and Neck Neoplasms / Q000188:drug therapy / Q000532:radiotherapy*; D006801:Humans; D008920:Misonidazole / Q000627:therapeutic use; D010043:Outcome and Process Assessment, Health Care / Q000592:standards; D011838:Radiation-Sensitizing Agents / Q000627:therapeutic use
D011838:Radiation-Sensitizing Agents; D008920:Misonidazole